secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016709
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports Q4/FY24 net loss $169M; cash $879.5M; zelenectide pevedotin shows 65% ORR in mUC
--------------------------------------------------------------------------------

- Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.
- Net loss $169.0M ($2.90 per share) for FY2024 vs $180.7M ($5.08 per share) in FY2023.
- Phase 1 Duravelo-1: 65% ORR (13/20) for zelenectide pevedotin + pembrolizumab in first-line mUC; no Grade 4/5 TRAEs of interest.
- FDA Fast Track granted for zelenectide pevedotin in NECTIN4-amplified TNBC and NSCLC; new Phase 1/2 trials planned in 2025.
- R&D expenses $173.0M in FY2024, up from $156.5M in FY2023, driven by zelenectide pevedotin development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/0001104659-25-016709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/tm257327d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer